BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Eli Lilly's Mounjaro enters Indian market, triggering a sharp rise in consultations as obesity rates climb and patients seek more accessible treatment options ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

The maker of Ozempic and the weight loss drug Wegovy told the FDA on April 3 that counterfeit 1-milligram injections were ...

The FDA and Novo Nordisk are warning of counterfeit Ozempic® (semaglutide) which could pose a safety risk. The FDA and ...

The Food and Drug Administration says it has seized several hundred units of fake versions of Ozempic. The drug maker Novo Nordisk told the FDA that the counterfeit 1-milligram injections were being ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

Novo Nordisk notified the Food and Drug Administration about several hundred units of fake semaglutide 1.0 mg in the US drug supply chain.

The maker of Ozempic and federal regulators are sending out warnings about counterfeit versions of the anti-diabetic drug ...

The maker of Ozempic and federal regulators are sending out warnings about counterfeit versions of the anti-diabetic drug ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...